Truist Financial Corp Cuts Stake in Boston Scientific Corporation $BSX

Truist Financial Corp lessened its position in Boston Scientific Corporation (NYSE:BSX) by 4.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 231,961 shares of the medical equipment provider’s stock after selling 10,118 shares during the period. Truist Financial Corp’s holdings in Boston Scientific were worth $22,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. Rathbones Group PLC boosted its position in shares of Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC acquired a new position in shares of Boston Scientific during the 4th quarter worth $1,477,000. Kepler Cheuvreux Suisse SA purchased a new position in shares of Boston Scientific in the 3rd quarter valued at about $26,955,000. Finally, Waycross Partners LLC purchased a new position in shares of Boston Scientific in the 4th quarter valued at about $2,384,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

NYSE:BSX opened at $56.00 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $83.23 billion, a P/E ratio of 23.43, a price-to-earnings-growth ratio of 1.03 and a beta of 0.62. The firm has a 50-day moving average price of $66.32 and a two-hundred day moving average price of $83.98. Boston Scientific Corporation has a twelve month low of $54.98 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on BSX. The Goldman Sachs Group decreased their price objective on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Robert W. Baird reduced their price target on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research report on Thursday, April 23rd. UBS Group lowered their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Finally, Canaccord Genuity Group dropped their price objective on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.